FDA Clears Encora X1 Wearable Device for Essential Tremor
The Encora X1 is a noninvasive, wrist-worn neurostimulation device designed to reduce hand tremors and improve daily function in adults with essential tremor.
The Encora X1 is a noninvasive, wrist-worn neurostimulation device designed to reduce hand tremors and improve daily function in adults with essential tremor.
Contrary to previous research, a new study of female participants finds no link between migraine and the risk of developing Parkinson’s disease.
A new study found that among those living with Parkinson’s disease, certain populations had a lower health-related quality of life than others.
People with neurologic diseases like headache, dementia, MS, and Parkinson’s disease may experience worsening symptoms due to climate change.
Read MoreThe annual incidence of Parkinson’s disease among older adults is 50% higher than current estimates of 60,000 diagnoses annually.
Read MoreA mutation in the misfolding protein that causes Parkinson’s offers protection against the neurodegenerative disease multiple system atrophy.
Read MoreThe Parkinson’s Foundation and Tag.bio announce a partnership that will help accelerate research into the causes and treatment of PD.
Read MoreResearchers used artificial intelligence techniques to estimate parameters such as step length, width, and velocity to diagnose Parkinson’s.
Read MoreEducation Series for Community Providers is a six-part online education series offering PD information for medically underserved communities.
Read MoreThe FDA-cleared Parky App monitors Parkinson’s symptoms such as tremors and dyskinesia in real time via the use of the Apple Watch.
Read MoreA second generation Integrated Motion Analysis Suite is being used as part of an NIH-funded trial investigating ESStim for Parkinson’s.
Read MoreENT-01 is safe for up to 25 days of treatment and helps improve constipation and possibly neurological symptoms in Parkinson’s patients.
Read MoreEsya Labs will be partnering with MSD to validate peripheral biomarkers for Parkinson’s disease and accelerate therapeutics development.
Read MoreEnterin Inc and Parkinson’s Virtual Biotech, part of Parkinson’s UK, are collaborating to study ENT-01 effects on Parkinson’s dementia.
Read MoreThe International Parkinson and Movement Disorder Society (MDS) is launching the first World Movement Disorders Day on November 29, 2022.
Read MorePeople with weight changes after Parkinson’s diagnosis may be more likely to have thinking skills changes than people who maintain weight.
Read MoreCMS’s decision expands access for Medicare patients with essential tremor who could benefit from Cala TAPS therapy.
Read MoreBy continuously monitoring a patient’s gait speed, the system can assess Parkinson’s severity between visits to the doctor’s office.
Read More